Acute Lymphoid Leukemia Clinical Trial
— EMTPOfficial title:
Erwinase Master Treatment Protocol
NCT number | NCT00590915 |
Other study ID # | Erwinase |
Secondary ID | IND-290 |
Status | No longer available |
Phase | N/A |
First received | December 26, 2007 |
Last updated | April 11, 2012 |
Verified date | April 2012 |
Source | Phoenix Children's Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Expanded Access |
The purpose of this study is to make Erwinase available to patients with acute lymphoblastic leukemia (ALL) who have had previous allergic reactions to certain formulations of L-asparaginase.
Status | No longer available |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Patient must give written informed consent to receive Erwinase. - Patient must be treated for acute lymphoblastic leukemia. - Patient must have either systemic hypersensitivity reactions to native (Elspar) or pegylated E.coli asparaginase (Oncaspar). This includes patients with generalized rash with or without anaphylactic symptoms, or patients with previously documented local or systemic reactions to E.coli derived L-asparaginase. Exclusion Criteria: - Previous allergic reaction to Erwinia L-asparaginase (Erwinase) - Previous acute pancreatitis - Pregnant or lactating woman |
N/A
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Phoenix Children's Hospital | Fisher Bioservices, Jazz Pharmaceuticals |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05959720 -
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
|
||
Recruiting |
NCT02933333 -
G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor
|
Phase 4 | |
Completed |
NCT02953730 -
The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents
|
Phase 4 | |
Completed |
NCT02767388 -
Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
|
||
Recruiting |
NCT03610438 -
Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia
|
Phase 2 | |
Recruiting |
NCT05792007 -
Study of the Medullary Microenvironment in Acute Childhood Leukemia
|
N/A | |
Completed |
NCT02294552 -
Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
|
Phase 2 | |
Completed |
NCT01461538 -
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
|
Phase 2 | |
Recruiting |
NCT04167683 -
Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant
|
||
Recruiting |
NCT05150561 -
Muscle Dysfunction in Patients With Haematological Diseases
|
||
Active, not recruiting |
NCT04669210 -
PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT
|
Phase 2 | |
Active, not recruiting |
NCT04013685 -
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
|
Phase 1 | |
Recruiting |
NCT02345915 -
Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia
|
N/A | |
Completed |
NCT01720264 -
Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant
|
Phase 2 | |
Not yet recruiting |
NCT02413021 -
The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens
|
Phase 1 | |
Not yet recruiting |
NCT06427330 -
Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia
|
Phase 2 | |
Active, not recruiting |
NCT04778579 -
Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy
|
Phase 2 | |
Recruiting |
NCT03448393 -
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
|
Phase 1 | |
Completed |
NCT03833180 -
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
|
Phase 1 | |
Active, not recruiting |
NCT03367299 -
Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia
|
Phase 2 |